Capolupo Irma, De Rose Domenico Umberto, Mazzeo Francesca, Monaco Francesca, Giliberti Paola, Landolfo Francesca, Di Pede Alessandra, Toscano Alessandra, Conforti Andrea, Bagolan Pietro, Dotta Andrea
Neonatal Intensive Care Unit, Medical and Surgical Department of Fetus - Newborn - Infant, "Bambino Gesù" Children's Hospital IRCCS, Rome, Italy.
Perinatal Cardiology, Medical and Surgical Department of Fetus - Newborn - Infant, "Bambino Gesù" Children's Hospital IRCCS, Rome, Italy.
Front Pediatr. 2023 Mar 29;11:1104728. doi: 10.3389/fped.2023.1104728. eCollection 2023.
Congenital Diaphragmatic Hernia (CDH) is a complex disease including a diaphragmatic defect, lung hypoplasia, and pulmonary hypertension. Despite its increasing use in neonates, the literature on the use of vasopressin in neonates is limited. The aim of this work is to analyze the changes in clinical and hemodynamic variables in a cohort of CDH infants treated with vasopressin.
Among CDH infants managed at the Neonatal Intensive Care Unit (NICU) of our hospital from May 2014 to January 2019, all infants who were treated with vasopressin, because of systemic hypotension and pulmonary hypertension, were enrolled in this retrospective study. The primary outcome was the change in oxygenation index (OI) after the start of the infusion of vasopressin. The secondary outcomes were the changes in cerebral and splanchnic fractional tissue oxygen extraction (FTOEc and FTOEs) at near-infrared spectroscopy, to understand the balance between oxygen supply and tissue oxygen consumption after the start of vasopressin infusion. We also reported as secondary outcomes the changes in ratio of arterial oxygen partial pressure (PaO2) to fraction of inspired oxygen (FiO2), heart rate, mean arterial pressure, serum pH, and serum sodium.
We included 27 patients with isolated CDH who received vasopressin administration. OI dramatically dropped when vasopressin infusion started, with a significant reduction according to ANOVA for repeated measures ( = 0.003). A global significant improvement in FTOEc and FTOEs was detected ( = 0.009 and = 0.004, respectively) as a significant reduction in heart rate ( = 0.019). A global significant improvement in PaO2/FiO2 ratio was observed ( < 0.001) and also at all time points: at 6 h since infusion ( = 0.015), 12 h ( = 0.009), and 24 h ( = 0.006), respectively. A significant reduction in sodium levels was observed as expected side effect ( = 0.012). No significant changes were observed in the remaining outcomes.
Our data suggest that starting early vasopressin infusion in CDH infants with pulmonary hypertension could improve oxygenation index and near-infrared spectroscopy after 12 and 24 h of infusion. These pilot data represent a background for planning future larger randomized trials to evaluate the efficacy and safety of vasopressin for the CDH population.
先天性膈疝(CDH)是一种复杂疾病,包括膈肌缺损、肺发育不全和肺动脉高压。尽管血管加压素在新生儿中的应用日益增多,但关于其在新生儿中应用的文献有限。本研究旨在分析一组接受血管加压素治疗的CDH婴儿的临床和血流动力学变量变化。
在2014年5月至2019年1月我院新生儿重症监护病房(NICU)收治的CDH婴儿中,纳入所有因系统性低血压和肺动脉高压接受血管加压素治疗的婴儿进行这项回顾性研究。主要结局是血管加压素输注开始后氧合指数(OI)的变化。次要结局是近红外光谱检测的脑和内脏组织氧摄取分数(FTOEc和FTOEs)的变化,以了解血管加压素输注开始后氧供应与组织氧消耗之间的平衡。我们还将动脉血氧分压(PaO2)与吸入氧分数(FiO2)之比、心率、平均动脉压、血清pH值和血清钠的变化作为次要结局进行报告。
我们纳入了27例接受血管加压素治疗的孤立性CDH患者。血管加压素输注开始时OI显著下降,重复测量方差分析显示有显著降低(P = 0.003)。检测到FTOEc和FTOEs总体有显著改善(分别为P = 0.009和P = 0.004),心率显著降低(P = 0.019)。观察到PaO2/FiO2比值总体有显著改善(P < 0.001),在所有时间点均如此:输注后6小时(P = 0.015)、12小时(P = 0.009)和24小时(P = 0.006)。观察到钠水平显著降低,这是预期的副作用(P = 0.012)。其余结局未观察到显著变化。
我们的数据表明,在患有肺动脉高压的CDH婴儿中早期开始血管加压素输注可在输注12小时和24小时后改善氧合指数和近红外光谱。这些初步数据为规划未来更大规模的随机试验以评估血管加压素对CDH人群的疗效和安全性提供了背景。